semaglutide cause kidney issues Cardio-kidney-metabolic protective effects of across the spectrum of chronic disease Taking the next step: the

[11] [12] There is a potential risk of pancreatitis

Adverse Reactions (2% and Greater Than Placebo) in WEGOVY-treated Adults with Obesity or Overweight for Weight Reduction In a CV outcomes trial, 8,803 patients were exposed to WEGOVY for a median of 37.3 months and 8,801 patients were exposed to placebo for a median of 38.6 months [see Clinical Studies (14.1)]

This medication mimics the effects of the hormone GLP-1, which plays a crucial role in reducing appetite and food absorption [1]

For an Indian generic player building a US portfolio do you win by chasing crowded markets, or by picking molecules where safety is the selling point

(2023, April 17)